Phase III clinical evaluation of gadoteridol injection: Experience in pediatric neuro-oncologic MR imaging
- 1 May 1992
- journal article
- clinical trial
- Published by Springer Nature in Pediatric Radiology
- Vol. 22 (2) , 93-98
- https://doi.org/10.1007/bf02011303
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Extravascular Toxicity of Two Magnetic Resonance Contrast AgentsInvestigative Radiology, 1991
- Reaction of gadolinium chelates with endogenously available ionsMagnetic Resonance Imaging, 1991
- Preliminary clinical trial of gadodiamide injection: A new nonionic gadolinium contrast agent for MR imagingJournal of Magnetic Resonance Imaging, 1991
- Phase III clinical evaluation of Gd-HP-DO3A in head and spine diseaseJournal of Magnetic Resonance Imaging, 1991
- Experimental trials with Gd(DO3A)—a nonionic magnetic resonance contrast agentNuclear Medicine and Biology, 1989
- Indications for the Use of Gd-DTPA in MRI of the Central Nervous System Experiences in Patients with Cerebral and Spinal DiseasesInvestigative Radiology, 1988
- Serum Iron and Serum Bilirubin After Administration of Gd-DTPA-Dimeglumine A Pharmacologic Study in Healthy VolunteersInvestigative Radiology, 1988
- Gd-DTPA in clinical MR of the brain: 1. Intraaxial lesionsAmerican Journal of Roentgenology, 1986
- Initial clinical evaluation of gadolinium DTPA for contrast-enhanced magnetic resonance imagingMagnetic Resonance Imaging, 1985
- Preparation and water relaxation properties of proteins labeled with paramagnetic metal chelatesMagnetic Resonance Imaging, 1985